Results 21 to 30 of about 218,137 (296)

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma [PDF]

Clinical Cancer Research, 2016
Abstract Purpose: The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Shintaro, Yokoyama, Hiroaki, Miyoshi, Kazutaka, Nakashima, Joji, Shimono, Toshihiro, Hashiguchi, Masahiro, Mitsuoka, Shinzo, Takamori, Yoshito, Akagi, Koichi, Ohshima   +8 more
openaire   +2 more sources

High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition

Diagnostics, 2021
Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT).
Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong   +3 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer [PDF]

Korean Journal of Clinical Oncology, 2017
Purpose Programmed death-1 and its ligands (PD-L1 and PD-L2) can induce T-cell apoptosis in many solid tumors, although there is limited information regarding their roles in colorectal cancer.
Jee Hyun Ahn, Hyun Yong Lee, Dong Hyun Kang, Geum Jong Song, Tae Sung Ahn, Myoung Won Son, Moon Soo Lee, Moo-Jun Baek   +7 more
doaj   +1 more source

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy [PDF]

Journal of Clinical Oncology, 2017
Purpose Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. Methods Patients who received anti–PD-1/PD-L1 monotherapy or in combination with anti–cytotoxic T-cell lymphocyte ...
Jarushka, Naidoo, Xuan, Wang, Kaitlin M, Woo, Tunc, Iyriboz, Darragh, Halpenny, Jane, Cunningham, Jamie E, Chaft, Neil H, Segal, Margaret K, Callahan, Alexander M, Lesokhin, Jonathan, Rosenberg, Martin H, Voss, Charles M, Rudin, Hira, Rizvi, Xue, Hou, Katherine, Rodriguez, Melanie, Albano, Ruth-Ann, Gordon, Charles, Leduc, Natasha, Rekhtman, Bianca, Harris, Alexander M, Menzies, Alexander D, Guminski, Matteo S, Carlino, Benjamin Y, Kong, Jedd D, Wolchok, Michael A, Postow, Georgina V, Long, Matthew D, Hellmann   +28 more
openaire   +2 more sources

Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer [PDF]

Journal of Oncology Practice, 2016
Programmeddeath 1 (PD-1)/programmed death ligand 1 (PD-L1) engagement is a physiologic process that inhibits the overactivation of T cells and thus serves to maintain self-tolerance and prevent autoimmunity. This mechanism is frequently hijacked by tumor cells, including lymphoma, when they aberrantly express PD-L1 (and PD-L2) proteins; however, this ...
openaire   +2 more sources

Nivolumab Enhances In Vitro Effector Functions of PD-1+ T-Lymphocytes and Leishmania-Infected Human Myeloid Cells in a Host Cell-Dependent Manner

Frontiers in Immunology, 2017
Functional impairment of T-cells and a concomitant augmented expression of programmed death-1 (PD-1) have been observed in visceral leishmaniasis patients, as well as in experimental models for visceral and cutaneous leishmaniasis.
Christodoulos Filippis, Katharina Arens, Gaetan Aime Noubissi Nzeteu, Gabriele Reichmann, Zoe Waibler, Peter Crauwels, Ger van Zandbergen, Ger van Zandbergen   +7 more
doaj   +1 more source

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Anti program death-1/anti program death-ligand 1 in digestive cancers

World Journal of Gastrointestinal Oncology, 2015
Human tumors tend to activate the immune system regulatory checkpoints as a means of escaping immunosurveillance. For instance, interaction between program death-1 (PD-1) and program death-ligand 1 (PD-L1) will lead the activated T cell to a state of anergy. PD-L1 is upregulated on a wide range of cancer cells.
Eléonore, de Guillebon, Pauline, Roussille, Eric, Frouin, David, Tougeron   +3 more
openaire   +2 more sources

Differential Requirement for CD70 and CD80/CD86 in Dendritic Cellmediated Activation of Tumor Tolerized CD8 T Cells [PDF]

, 2012
A major obstacle to efficacious T cell-based cancer immunotherapy is the tolerizing-tumor microenvironment that rapidly inactivates tumor-infiltrating lymphocytes.
Bai, Ailin, Bak, Peter, Barnkob, Mike Stein, Chen, Jianzhu, Higham, Eileen M., Wittrup, Karl Dane   +5 more
core   +1 more source